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The pathogenesis of clinically evident lung cancer involves the 
acquisition of multiple genetic and epigenetic changes (on the order of 
10-20 genes) in lung epithelial cells. This usually occurs after smoking 
exposure. Genome wide approaches as well as study of multiple 
individual genes have identiﬁed several key genes which fall into 
different components of the “Hallmarks of Cancer”. Genome wide 
approaches include genome wide mRNA expression proﬁling using 
microarrays, genome wide array based CGH analysis (aCGH), genome 
wide epigenetic approaches, genome wide microRNA (miRNA) 
expression proﬁling, large scale gene sequencing for mutation 
detection, genome wide siRNA and shRNA knockdowns (e.g. knock-
down of all kinases), and large scale proteomics analysis such as with 
reverse phase protein arrays (RPPAs). These have led to the identiﬁca-
tion of a large number of new genes, miRNAs, and activated proteins 
involved in lung cancer pathogenesis. Some examples include 
discovery of new mutated and ampliﬁed genes likely serving as 
oncogenes such as TITF1, MET, and PI3K, changes in miRNA 
expression proﬁles, and multiple new genes that are methylated in lung 
cancer pathogenesis and thus are likely to function as tumor suppressor 
genes. In addition, there are changes in gene expression of key genes 
likely to be involved in the pathogenesis of different types of lung 
cancer such as differences in patterns of expression of nAChRs subunit 
genes in adenocarcinomas arising in smokers vs. never smokers. The 
challenge is to apply these ﬁndings to improve diagnosis, prognosis, 
therapy and prevention of lung cancer. One way this translation to the 
clinic occurs early is testing the expression of the genes via immuno-
histochemistry or through FISH in tissue microarrays (TMAs) of lung 
cancer involving large numbers of clinically annotated (1,000) 
specimens including preneoplastic lesions. Biomarkers for Early 
Diagnosis For early diagnosis studies of preneoplastic lesions and even 
histologically normal epithelium have identiﬁed some of the changes as 
occurring at very early stages including loss of heterozygosity at 
chromosome regions 3p (multiple sites) and 9p (p16 site). The 
development of molecular markers that could be detected in sputum or 
bronchial brushes of persons at highest risk of developing lung cancer 
would be advantageous. Methylated DNA sequences associated with 
RASSF1A and p16 are such candidates. Several groups have demon-
strated detection of methylated DNA sequences in the sputum of 
patients going onto develop lung cancer. Recently, proteomic analysis 
of lung cancers and serum from lung cancer patients have identiﬁed 
markers and proteomic patterns that should aid in predicting which 
persons are at highest risk of developing lung cancer. As part of this 
detecting cytokine angiogenic factors (CAFs) that are produced by 
tumor cells and can be detected in the blood of patients are particularly 
attractive markers. All of these need to be integrated with ongoing 
studies of CT screening for lung cancer. Inherited Susceptibility to 
Lung Cancer The Genetic Epidemiology of Lung Cancer Consortium 
(GELCC) has collected families with a strong family history of lung 
cancer and from these performed linkage studies which have identiﬁed 
a locus at 6q23 which in affected individuals leads to a very high risk 
of developing lung cancer. The region has been narrowed down to ~100 
genes which are now being sequenced. The identiﬁcation of this locus 
has provided for tests of the role of smoking in obligate carriers vs. 
non-carriers and led to the ﬁnding that carriers who are non-smoking 
have an increased risk of developing lung cancer, but more importantly 
that any degree of smoking (even light smoking) greatly increases this 
risk. Such genetic differences between individuals are being incorpo-
rated with epidemiology data to derive new risk assessment models of 
predicting who is most likely to develop lung cancer. Targeted 
Therapy for Lung Cancer Mutations in the tyrosine kinase (TK) 
domain of the epidermal growth factor receptor (EGFR) have been 
discovered in ~5-10% of lung cancer patients, particularly in patients 
with adenocarcinoma of the lung arising in never smokers, females, and 
East Asians. These mutations appear to make the EGFR oncogenic but 
also make the tumor cells exquisitely sensitive to TK inhibitors (TKIs) 
such as geﬁtinib and erlotinib (oral agents with little toxicity). These 
therapies provide substantial clinical remissions for such patients. In 
addition, other mutations (such as EGFR T790M, and MET ampliﬁca-
tion) can give resistance to EGFR TKIs and drugs which can bypass 
this resistance are being sought. However, even more important are 
developing drugs that would targeted other oncogenes that are mutated 
or ampliﬁed in lung cancer and to which lung cancer cells are “ad-
dicted” such as MET, TITF1, PI3K, BRAF, and oncogenic KRAS. 
Lung Cancer Expression Proﬁles of Clinical Beneﬁt Genome wide 
oligonucleotide mRNA and protein (proteomic) expression proﬁles of 
lung cancer have shown that different lung cancer types have different 
proﬁles, that lung cancers with different prognoses have different 
proﬁles, and more recently that lung tumors that have different 
sensitivities to chemotherapy have distinct gene and protein expression 
signatures. This offers the possibility of testing a patient’s tumor before 
treatment to help with prognosis and to select individualized therapy. 
The key to this will be to obtain clinically annotated specimens that 
link a patient’s response to therapy with a tumor tissue sample. As part 
of this is developing genetic biomarkers predicting response to 
radiation of tumor cells. One new example of this, is the recently 
discovered (an unexpected) sensitivity of lung cancers with EGFR TK 
domain mutations to radiation. Preclinical Model Lung Cancer 
System for Drug and Expression Proﬁle Signature Development An 
important component of developing such predictive biomarker 
signatures is the validation of preclinical model systems for testing 
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drugs and combinations of therapy including lung cancer cell lines, 
xenografts, including orthotopic (lung) xenografts and xenografts made 
directly from patient samples without intervening cell culture. For this 
reason we have developed a very large (>200) panel of lung cancer cell 
lines of all histologic types and including all of the various genetic 
changes found in lung cancer. Coupled with this we have developed 
xenograft models (including orthotopic models) of lung cancer in >50 
lung cancers including xenografts made from lung cancer lines and 
from primary patient materials. We can determine expression proﬁles in 
these preclinical models as a step toward developing biomarker 
signatures that can be tested in the clinic. The use of bioluminescence 
imaging (BLI) to help follow the growth and response of xenografts to 
therapy is an important new tool. From all of these we need to know 
how good or bad such preclinical model systems are in both identifying 
drug response phenotypes and in developing predictive signatures that 
will work in patient specimens. For example the whole EGFR TKI 
story coupled with EGFR TK domain mutations as well as EGFR TKI 
resistance was present in the large panel of lung cancer cell lines and 
xenografts we have developed. Because of this we have been testing 
several new drugs in development alone and in combination such as a 
SMAC mimetic and Peloruside A. We have found not only dramatic 
differences between lung cancer cells in response to the drugs as single 
agents, but complex patterns of synergy (which are often dramatic) 
when they are combined with standard drugs. Genome Wide Ap-
proaches to Discovery of New Therapeutic Targets Including 
Synthetic Lethal Screens Large scale DNA sequencing and DNA 
ampliﬁcation screens are going on to ﬁnd oncogenic changes that repre-
sent “druggable” targets. However, another approach that is gaining 
attention are genome wise functional screens for such targets such as 
genome wide screening of siRNA and shRNA libraries for genes that 
when knocked down sensitize tumor cells to low doses of chemothera-
py agents. This approach has led to the discovery of 87 genes, which 
when knocked down by siRNAs dramatically sensitize lung cancer 
cells to paclitaxel. This information could provide “signatures” for 
predicting paclitaxel response, but also targets that could be addressed 
in combination with paclitaxel. Some of these (such as a panel of 
cancer testis antigen genes) are selectively expressed in tumor cells. Of 
course these siRNA/shRNA screens can be coupled with screening of 
small molecule libraries. Related to this is miRNA proﬁling which 
identiﬁed two miRNAs whose expression was inversely correlated with 
paclitaxel resistance. By re expressing these two miRNAs, paclitaxel 
resistant lung cancers were converted to a paclitaxel sensitive pheno-
type. Thus, such miRNAs can be considered for therapeutic develop-
ment. Lung Cancer Stem Cells There is considerable evidence 
mounting that a small subset of lung cancer cells (~1% or less of the 
total tumor cell population) has the properties consistent to give immor-
tal and metastatic disease and are referred to as “cancer stem cells” or 
“stem-like” cells. We have developed ways to isolate and study these 
cells and they have clear differences in gene expression programs for a 
variety of stem cell proliferation genes as well as increased ability to 
clone in soft agar, form tumors in xenografts, and give metastatic 
disease in xenografts. Key issues will be to develop good, easy to use 
markers (such as monoclonal antibodies) to identify these cells, to see 
how their response to therapy compares with the bulk of the tumor 
(since it is likely they may be more resistant to therapy), and whether 
their presence or amount is of prognostic signiﬁcance. Of course their 
identiﬁcation in preneoplastic stages will be important as new molecu-
lar markers for early lung cancer detection. New Model Systems for 
Studying Lung Cancer Pathogenesis In order to determine which 
steps are most important we have developed a new system for 
immortalizing human bronchial epithelial cells (HBECs) in the absence 
of viral oncoproteins using hTERT (human telomerase providing part 
of the immortalization pathway) and cdk4 (bypassing the p16/Rb 
checkpoint) expression vectors. We have established over 30 such 
strains from persons with and without lung cancer. These expressed 
stem cell markers, can differentiate in 3 dimensional cultures into 
ciliated epithelium and are do not expression malignant properties. We 
have added oncogenic KRAS (found in 30% of non-small cell lung 
cancers, NSCLC) and knocked out p53 (found in 50% of all lung 
cancers) alone or together. These (together with hTERT and cdk4) only 
partially progress the HBECs toward malignancy. We have also made 
changes in multiple other genes such as CMYC, BCL2, PTEN, and 
EGFR and ﬁnd that again these only partially progress HBECs towards 
malignancy. However, combining KRASV12, p53 knockdown, and 
CMYC coupled with biologic selection in SCID mice can identify a 
subset of fully malignant tumor cells. IN addition, the addition of these 
oncogenic changes leads to changes in cytokine secretion patterns that 
provide new information for early lung cancer detection through 
screening for these cytokines in blood. These HBECs are providing a 
new model for systematically testing the importance of additional 
genetic changes in lung cancer pathogenesis. In developments by 
several other groups, mouse models of lung cancer have been devel-
oped based on genetic abnormalities found in human lung cancer with 
development of mouse systems for speciﬁc development of these 
abnormalities in lung as a target tissue. These have been developed for 
non-small cell lung cancer (NSCLC) (based on oncogenic KRAS) and 
for small cell lung cancer (SCLC) (based on p53 and Rb abnormali-
ties). These models are proving extremely valuable in the preclinical 
testing of early detection, chemoprevention, and new treatment 
strategies. 
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The pulmonary environment presents a unique milieu in which lung 
carcinogenesis proceeds in complicity with the host cellular network. 
The pulmonary diseases that are associated with the greatest risk for 
lung cancer are characterized by abundant and deregulated inﬂam-
mation. Pulmonary disorders such as chronic obstructive pulmonary 
disease (COPD)/emphysema and pulmonary ﬁbrosis are characterized 
by profound abnormalities in inﬂammatory-ﬁbrotic pathways. For 
example, among the cytokines and growth factors aberrantly produced 
in these lung diseases and the developing tumor microenvironment 
(TME), IL-1β, PGE2, and TGF-β have been found to have deleteri-
ous properties that simultaneously pave the way for both epithelial 
mesenchymal transition (EMT) as well as destruction of speciﬁc host 
cell-mediated immune responses. Loss of E-cadherin expression by 
epithelial cells is a characteristic of EMT and is associated with pro-
gression of lung cancer. Our recent work and that of others implicates 
E-cadherin expression as a marker of sensitivity to epidermal growth 
factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in NSCLC. 
In fact a biological signature that would allow for the detection of 
EGFR TKI-sensitive NSCLC tumor cells with an activated EGFR 
pathway has recently been identiﬁed, independent from the mecha-
nism leading to activation. A gene signature indicative of an epithelial 
